What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI

• https://x.com/RHEUMarampa/status/2063183753086706014/photo/1
• https://x.com/RHEUMarampa/status/2063183753086706014/photo/1

Good performance of #definite #antisynthetase #syndrome ✅+antibody mandatory Possible also does ok @RheumNow #EULAR2026 June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT

• https://x.com/Janetbirdope/status/2063188722951020970/photo/1
• https://x.com/Janetbirdope/status/2063188722951020970/photo/1
• https://x.com/Janetbirdope/status/2063188722951020970/photo/1

Dr. Cavagna presents the 2025 EULAR/ACR Classification Criteria for Anti-Synthetase Syndrome He emphasizes the inportance of ruling out anti-MDA5 Ab & anti-PM/Scl Ab DM since these conditions share overlapping features w/ ASyS. @RheumNow #EULAR2026 https://t.co/AtGRlp5qyW

• https://x.com/RHEUMarampa/status/2063190218740564267/photo/1
• https://x.com/RHEUMarampa/status/2063190218740564267/photo/1
• https://x.com/RHEUMarampa/status/2063190218740564267/photo/1
• https://x.com/RHEUMarampa/status/2063190218740564267/photo/1

Do u screen your SLE pts for OP? In this real-world multicenter study, SLE pts who were likely to be tested for BMD were older, had MSK s/sxs, sSJg & longer GC exposure. RFs for OP: LN, higher dse. activity, longer GC use, high cumulative GC dose POS1372 @RheumNow #EULAR2026 https://t.co/pAxhOPGGYs

• https://x.com/RHEUMarampa/status/2063309057927024864/photo/1

#EULAR2026 POS1139 Pay attention in #SLE with anti-Sm+ RNP+. Data from 3 RCTs & a cohort: -enriched in Black patients -poor response to B-cell depletion inc. Obi -non-response is assoc. with BAFF-dependent B-cell repopulation. So, use Belimumab -High ferritin = flare @RheumNow https://t.co/3uDMigY8i2

• https://x.com/Yuz6Yusof/status/2063280229594890649/photo/1

Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia

• https://x.com/synovialjoints/status/2063222707315974230/photo/1

Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO

• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1

#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC

• https://x.com/Yuz6Yusof/status/2063227779928166838/photo/1
• https://x.com/Yuz6Yusof/status/2063227779928166838/photo/1

#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY

• https://x.com/Yuz6Yusof/status/2063230586743927190/photo/1
• https://x.com/Yuz6Yusof/status/2063230586743927190/photo/1

JASMINE-SLE: Proof of concept study on Nipocalimab for SLE SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO Improvement of SRI-4 composite & LLDAS at wk 52 LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy

• https://x.com/RHEUMarampa/status/2063234107761414619/photo/1
• https://x.com/RHEUMarampa/status/2063234107761414619/photo/1

#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v

• https://x.com/Yuz6Yusof/status/2063245455014633559/photo/1

5 top abstracts in #Myositis @eular_org 1 #Nailfold #capillaries as an early marker of #IIM Rx 2 #brepocitinib +RCT #DM 3 & rapid skin improvement #CLASI 4 #Ab may help #IBM but neg primary endpoint 5 #criteria for #antisynthetase #EULAR2026 @RheumNow OP0168, 0166, 0164 POS264